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onsteroidal Anti-Inflammatory
rugs and Cardiovascular Risk
s Prostacyclin
nhibition the Key Event?*
ietro Minuz, MD
erona, Italy
electivity toward cyclooxygenase (COX)-2 is usually de-
ned by comparing the capacity of individual nonsteroidal
nti-inflammatory drugs (NSAIDs) to inhibit in vitro or ex
ivo the generation of thromboxane A2 (TXA2) through
OX-1 in aggregating platelets with the capacity to inhibit
rostaglandin (PG) E2 generation through COX-2, ex-
ressed in leukocytes after an inflammatory stimulus (1).
his rather simple test has been regarded as the most useful
ool to define a priori the gastric tolerability and potential
nti-inflammatory capacity of new NSAIDs, but has turned
ut to be a criterion to identify potential cardiovascular
amage associated with the use of selective or nonselective
OX-2 inhibitors and to interpret the results of clinical
rials.
See page 1628
The assumption that COX-2 was primarily involved in
he inflammatory response was put into doubt by the finding
hat this enzyme is implicated in cardiovascular homeosta-
is. The hypothesis that this is related to inhibition of
asodilatory and antiaggregatory prostacyclin (PGI2) derives
ainly from the seminal observation that administration of
elective COX-2 inhibitors results in reduced excretion of a
ajor PGI2 metabolite (namely, 2,3-dinor-6 keto-PGF1),
biomarker of synthesis (2). Indirect support has also been
rovided by showing that deletion or mutation of PGI2
eceptors accelerates the development of atherosclerosis in
he presence of vascular injury or cardiovascular risk factors,
nd allows TXA2 to exert unopposed prothrombotic activ-
ties (3,4). In addition, reduced vascular and renal produc-
ion of prostanoids by COX-2 may contribute to cardiovas-
ular risk by inducing sodium retention and increasing
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.c
From the Department of Biomedical and Surgical Sciences, Section of Internal
edicine, University of Verona, Verona, Italy.rterial pressure, as observed in susceptible subjects treated
ith NSAIDs (5,6).
When the COX-2 to COX-1 inhibition ratio is calcu-
ated, a broad range of values is defined in which one
xtreme is occupied by the irreversible inhibitor of platelet
OX-1 and cardioprotective aspirin (low doses) (7), while
ighly selective COX-2 inhibitors are found at the other
xtreme (6).
In some cases, high selectivity toward COX-2 inhibition
elates to clinical outcomes and offers a plausible explanation
f the underlying mechanism, as is the case of rofecoxib (8).
owever, in some clinical trials, the incidence of cardiovas-
ular events is not different when drugs with different
electivity toward COX-2 have been compared, as is the
ase for etoricoxib and diclofenac (9). It may be inferred that
ther factors related to pharmacodynamics and pharmaco-
inetics of individual compounds, intensity of treatment,
nd the clinical characteristics of the studied patients con-
ribute to differences in clinical outcomes. Traditional
SAIDs may show a pattern of COX-2 selectivity similar
o that of COX-2 inhibitors, coxibs, as is the case of
iclofenac when compared with celecoxib, or may be more
ctive as COX-1 inhibitors, as for naproxen and ibuprofen
6,10).
There is a need to verify the clinical safety of NSAIDs in
he absence of randomized placebo-controlled clinical trials
egarding the cardiovascular adverse effects of traditional
SAIDs and in light of retrospective studies showing that
ome NSAIDs are associated with increased cardiovascular
isk (11). Indeed, new criteria to identify cardiovascular risk
n different therapeutic regimens of individual NSAIDs are
eeded.
In this issue of the Journal, Garcı´a Rodrı´guez et al. (12)
dd substantial new information to this highly debated topic
y showing increased cardiovascular risk associated with the
se of NSAIDs in clinical practice, and they offer a novel,
omprehensive explanation for the observed risk. This was a
etrospective case-control study, nested in a population-
ased data collection, where the end point was myocardial
nfarction. Patients were treated with traditional NSAIDs
r coxibs and were grouped as current, recent, and past
sers. Attention was also paid to minimization of biases:
utomated data collection was validated by manual review in
random sample, and new users were identified and
valuated for cardiovascular risk to include early events
ssociated with treatments that could have been missed by
tudying previously exposed subjects. Exposure to NSAIDs
as analyzed taking into account the intensity and duration
f treatment as well as the pharmacokinetic characteristics
f each individual drug. Overall, a statistically significant
ncrease in relative risk (RR), by 35%, of myocardial
nfarction was observed; significantly higher values were
bserved with diclofenac (RR: 1.67) and rofecoxib (RR:
.47). These results are consistent with those of previous
ase-control studies and randomized clinical trials (11,13),
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oward COX-2 is a necessary requirement for cardiovascular
isk. In fact, they found that prolonged efficacy and higher
oses, and therefore higher levels of active compound, are
ssociated with an increased risk for any given drug. This
nding suggests that the degree of COX inhibition by
herapeutic levels of NSAIDs should be considered the
ajor determinant of cardiovascular risk (6,12,14).
To test this hypothesis, the authors explored, and found,
correlation between the relative risk of myocardial infarc-
ion while a patient was treated with an NSAID and the
egree of COX-2 inhibition obtained in vitro using con-
entrations of NSAIDs similar to those found in vivo at
herapeutic doses.
Acting as inhibitors of COX-1, traditional NSAIDs may
etain some antiplatelet activity from the inhibition of
XA2 (6,10,15). However, it is now clear that TXA2 is
xtremely effective as a platelet activator, and that its
iosynthesis is strictly controlled and only small amounts are
ctually released in vivo (7,16). Therefore, to prevent the
mplification process in platelet activation, the synthesis of
XA2 must be virtually abolished because residual amounts
approximately 5% of the maximal platelet synthetic capac-
ty) would be adequate to induce the activating signals
equired for platelet aggregation (7,17). That explains why
ery few compounds, even when given at adequate, regular
oses for prolonged periods, can match the degree of
nhibition that is obtained through the irreversible acetyla-
ion of COX-1 caused by aspirin (7). This inhibition may
ccur with therapeutic doses of naproxen, which can
educe the release of TXA2 from platelets to the same
xtent reached by aspirin, acting as a reversible inhibitor
f COX-1 (15).
From the data presented by Garcı´a Rodrı´guez et al. (12),
either naproxen nor ibuprofen increase relative cardiovas-
ular risk, and have either effective anti–COX-1 or poor
nti–COX-2 activities. Moreover, the concomitant use of
SAIDs does not appear to increase the risk of myocardial
nfarction in subjects treated with aspirin, unless competi-
ion with certain NSAIDs occurs, thus supporting the
oncept of the protective effect given by inhibition of TXA2
iosynthesis in platelets (12). Therefore, increase in cardio-
ascular risk appears to be indissolubly linked to effective
nhibition of COX-2, unless mitigated by the concomitant
ffective inhibition of platelet COX-1.
The authors propose a model to interpret the epidemio-
ogic data and have devised a test to define a priori both the
fficacy and the potential harm of individual NSAIDs. If a
rug is unable to determine in vitro at least 95% of
nhibition in TXA2 released from platelets, the cardiovas-
ular hazard increases, provided that COX-2 activity is
nhibited by at least 90%. Given that vasculature and
OX-2 have been shown to be major sources and catalysts
f PGI2 (6), the authors infer that only a profound reduc-
ion in COX-2 activity translates into a substantial reduc-
ion in PGI2 synthesis in vivo, and eventually into increasedisk of myocardial infarction (12). This finding is the most
nteresting and provocative part of the study. For the first
ime, numerical data are introduced to analyze (and not
erely discuss) the possible link between clinical events and
he degree of COX-2 inhibition. Moreover, a threshold is
efined, beyond which any further reduction in PGI2
iosynthesis likely determines vascular dysfunctionality and
prothrombotic state. To reinforce this concept, the au-
hors show in the supplementary data that there is correla-
ion between residual urinary excretion of 2,3-dinor-6
eto-PGF1 after the administration of some NSAIDs and
egree of COX-2 inhibition (12).
The proposed paradigm certainly needs confirmation.
e do not know when low residual biosynthesis of PGI2 is
ctually too low to cause cardiovascular dysfunction or
amage, and we do not know whether this threshold is
qual in different clinical settings or whether different
mounts are required to maintain homeostasis, particularly
hen the nitric oxide system is defective, as the increased
isk observed in patients with previous myocardial infarction
ay suggest (12). The use of validated biomarkers in
elation to measurable cardiovascular phenomena or clinical
vents may help define the elusive role of vascular COX-2
nd PGI2 in cardiovascular medicine.
The dyad PGI2-TXA2 may regain its centrality in the
omplex picture that has been offered by molecular and
harmacological investigations. Further research is required.
eprint requests and correspondence: Dr. Pietro Minuz, Medi-
ina Interna C, Policlinico GB Rossi, 37134 Verona, Italy.
-mail: pietro.minuz@univr.it.
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